-- 根據彭博社週四發布的分析報告顯示，受伊朗戰爭影響，美國汽油價格飆升，加州汽油價格突破每加侖6美元，中西部地區汽油價格達到每加侖4.67美元，柴油價格接近每加侖7.50美元。 分析報告指出，繼亞洲和歐洲油價連續數週上漲後，美國各地的燃油價格也大幅攀升，與衝突相關的能源衝擊持續在全球市場蔓延。 分析報告引述美國汽車協會（AAA）的數據稱，加州普通汽油的平均價格週三超過每加侖6美元，創下自2023年10月以來的最高水準。 分析報告也指出，伊利諾州汽油價格達到每加侖4.67美元，比去年平均高出1美元多；印第安納州、密西根州和俄亥俄州等地區市場也出現了類似的油價飆升。 分析報告顯示，柴油價格與汽油價格同步上漲，加州柴油價格接近每加侖7.50美元，中西部地區柴油價格則維持在每加侖5美元左右。 分析顯示，美國汽油期貨價格升至近四年來的最高水準。 分析指出，伊朗衝突已進入第九週，交易員越來越擔心霍爾木茲海峽（重要的石油運輸通道）會長期中斷或封鎖。 分析也指出，燃料價格上漲正成為共和黨在中期選舉前面臨的政治挑戰，尤其是在密西根州和俄亥俄州的參議院選舉中。 分析稱，加州油價飆升給州長加文紐森帶來了壓力，他可能考慮參加2028年總統競選。 分析引述伍德麥肯茲的數據顯示，中西部煉油廠的營運問題加劇了供應緊張，其中包括埃克森美孚位於喬利埃特的煉油廠一個關鍵加工裝置的停產。 分析指出，英國石油公司位於印第安納州懷廷的煉油廠發生的另一起電力中斷事件，即使其他設施仍在運行，也加劇了不確定性，導致區域燃油價格持續波動。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN